Alessa Therapeutics Inc. Report issue

For profit Phase 1
Founded: San Carlos California United States (2018)

Organization Overview

First Clinical Trial
2020
NCT04284761
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Alessa Therapeutics Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

bicalutamide (casodex) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Lower Urinary Tract Symptoms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 1